Continuing the huge trend of discovering more into the magical "immune checkpoint blockade" therapy (as the hottest field that shed hope to cancer treatment), more is to be discussed about them. As is designed to battle against body's own mechanisms that suppress immune cells, those drugs as Ipilimumab and Nivolumab potentiate patients' own immune systems so that they are able to do their jobs and to control tumor growth. Despite the exciting efficacy of these drugs in melanoma, one of the puzzles is the different reponsiveness among patients. Two papers just came out about the topic. While Ipilimumab (CTLA-4 inhibitor) and Nivolumab (PD-1 inhibitor) were individually discussed in each paper, similar correlation of the responsiveness of immune checkpoint blockade therapy with genomic alteration in melanoma patients were found. High mutation loads tend to correlate with a favorable clinical response of both Ipilimumab and Nivolumab. However as suggested in the S...